BDBM304444 (R)-(4-(3-isopropyl-4-(5-(prop-1-en-2-yl)-4-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)-2-(methylsulfonyl)phenyl)methanol::US10144715, Compound 14-2
SMILES: CC(C)[C@@H]1CN(CCN1c1ncc(C(C)=C)c(n1)C(F)(F)F)c1ccc(CO)c(c1)S(C)(=O)=O
InChI Key: InChIKey=ZIFRSVSKYBFYNR-IBGZPJMESA-N
Data: 1 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oxysterols receptor LXR-beta (Homo sapiens (Human)) | BDBM304444 ((R)-(4-(3-isopropyl-4-(5-(prop-1-en-2-yl)-4-(trifl...) | GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Vitae Pharmaceuticals, Inc. US Patent | Assay Description Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan... | US Patent US10144715 (2018) BindingDB Entry DOI: 10.7270/Q2PV6NFD | |||||||||||
More data for this Ligand-Target Pair |